Original Query: ALL
Previous Study | Return to List | Next Study

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00567554
Recruitment Status : Completed
First Posted : December 5, 2007
Last Update Posted : February 10, 2016
AGO Study Group
Information provided by (Responsible Party):
German Breast Group

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : August 2011
  Study Completion Date : October 2015
Publications automatically indexed to this study by Identifier (NCT Number):